A novel class of antagonists for metabotropic glutamate receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates

https://doi.org/10.1016/0960-894X(96)00104-7Get rights and content

Abstract

7-(Hydroxyimino)cyclopropa[b]chromen-la-carboxylates (4a-c), highly potent antagonists for a phospholipase C-linked metabotropic glutamate receptor, mGluR1, were synthesized through cyclopropanation onto 4-oxo-4H-1-benzopyran-2-carboxylates (5a-c) utilizing dimethyloxosulfonium methylid followed by treatment with hydroxylamine.

The synthesis of 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates (4a-c), highly potent antagonists for a phospholipase C-linked metabotropic glutamate receptor, mGluR1, is described.

  1. Download : Download full-size image

References (29)

  • D.D. Schoepp et al.

    Trends Pharmacol. Sci.

    (1993)
  • S. Nakanishi

    Neuron

    (1994)
  • J. Watkins et al.

    Trends Pharmacol. Sci.

    (1994)
  • Y. Tanabe et al.

    Neuron

    (1992)
  • I. Aramori et al.

    Neuron

    (1992)
  • T. Abe et al.

    J. Biol. Chem.

    (1992)
  • E. Palmer et al.

    Eur. J. Pharmacol.

    (1989)
  • A.J. Irving et al.

    Eur. J. Pharmacol.

    (1990)
  • M. Ishida et al.

    Brain Res.

    (1990)
  • M. Ishida et al.

    Neurosci. Lett.

    (1993)
  • D. Schoepp et al.

    Trends Pharmacol. Sci.

    (1990)
  • S. Nakanishi

    Science

    (1992)
  • M. Hollmann et al.

    Annu. Rev. Neurosci.

    (1994)
  • T. Knopfel et al.

    J. Med. Chem.

    (1995)
  • Cited by (171)

    • Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors

      2019, Trends in Pharmacological Sciences
      Citation Excerpt :

      In functional assays such as those that measure calcium mobilization, the effect of a PAM is often to induce a leftward shift of the agonist concentration–response curve, while a NAM will decrease the maximal effect of the response. The first allosteric modulator of mGlu receptors identified was the mGlu1 NAM, CPCCOEt [6]; a compound that was shown to inhibit mGlu1 receptor signaling without affecting glutamate binding [7]. This was followed shortly by the discovery of the first selective mGlu5 NAMs, SIB-1757 and SIB-1893 [8].

    • Allosteric modulators targeting GPCRs

      2019, GPCRs: Structure, Function, and Drug Discovery
    • Molecular insights into allosteric modulation of Class C G protein-coupled receptors

      2017, Pharmacological Research
      Citation Excerpt :

      The clinical success of CaSR PAMs provides the promise that allosteric modulators of other Class C GPCRs will offer new therapeutics. Although the mGlu1 NAM, CPCCOEt, was the first mGlu allosteric ligand disclosed [191,192], the mGlu5 NAM, fenobam, was discovered much earlier [193]; however, its target was not elucidated until many years later [194]. Intensive directed discovery efforts have subsequently yielded selective and pharmacologically diverse allosteric ligands for the majority of mGlu family members (Table 1).

    • Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain

      2015, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Additionally, suppressing the activation of mGluR1 via genetic knockdown or small molecule antagonists attenuated nociceptive responses in animal models of pain [19–25] indicating that mGluR1 is associated with chronic pain and can serve as a promising target for the treatment of neuropathic pain [26,27]. Since the first non-competitive antagonist of mGluR1, CPCCOEt, was identified [28,29], many small molecule antagonists were developed and utilized to establish the location and structure of the allosteric binding site [30]. Furthermore, with the help of the structural information, a number of highly potent allosteric antagonists of mGluR1 have been reported to date, and several examples are shown in Fig. 1.

    View all citing articles on Scopus
    View full text